Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.

ABSTRACT:

Objectives

To describe the efficacy and safety through 5 years of adalimumab treatment in patients with ankylosing spondylitis (AS), and to identify predictors of remission.

Methods

Patients with active AS were followed up to 5 years during a 24-week randomised, controlled period, followed by an open-label extension. Disease activity and clinical improvement were evaluated by Assessment in Spondyloarthritis International Society (ASAS) responses, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS). Kaplan-Meier was used to identify patients with sustained ASAS partial remission (PR) or ASDAS inactive disease (ID) for three or more consecutive visits spanning ≥ 6 months. Logistic regression was used to identify

SUBMITTER: Sieper J 

PROVIDER: S-EPMC3329233 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature